Immune checkpoint blockers (ICBs) have been associated with a variety of dermatologic
adverse reactions. Macular rashes, eczematous and lichenoid reactions, vitiligo, psoriasis
and pruritus are some of the most frequently observed and well-known cutaneous toxicities.
[1]
However, skin reactions derived from ICBs have a wide clinical spectrum, leading
to a variety of clinical entities. Therefore, clinicians need to be watchful when
they encounter skin reactions. We present the first cases of ichthyosis triggered
by ICBs, and we describe the clinical characteristics, the therapeutic interventions,
and treatment outcomes of this unusual ICB-induced toxicity.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy.Am J Clin Dermatol. 2018; 19: 345-361
- Ichthyosis etiology, diagnosis and management.Am J Clin Dermatol. 2003; 4: 81-95
- Panotinib-induced lamellar ichthyosis-like eruption.Int J Dermatol. 2020; 59: e156-e157
- Hair repigmentation during immunotherapy treatment with an anti-programmed cell death 1 and anti-programmed cell death ligand 1 agent for lung cancer.JAMA Dermatol. 2017; 153: 1162-1165
- Prurigo nodularis and pembrolizumab: a therapeutic challenge.Eur J Cancer. 2019; 110: 8-10
Article info
Publication history
Published online: August 15, 2022
Accepted:
July 7,
2022
Received in revised form:
May 23,
2022
Received:
April 26,
2022
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
